Urothelial Cancer

Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.

Drs Armstrong and Tawagi provide a comprehensive review of metastatic urothelial carcinoma management.

Timothy N. Clinton, MD, discusses initiatives to improve outcomes for female patients with bladder cancer.

Timothy N. Clinton, MD, discusses biologic and anatomical differences underlying sex and gender disparities in bladder cancer incidence.

The FDA grants priority review to enfortumab vedotin-ejfv sBLAs in MIBC, the review period for subcutaneous isatuximab BLA in myeloma has been extended, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

A response to neoadjuvant chemotherapy was associated with long-term survival benefits in high-risk UTUC.

Sac-TMT produced durable responses with a manageable safety profile in pretreated advanced/metastatic urothelial carcinoma.

The FDA has granted priority review to the sBLAs for pembrolizumab and subcutaneous pembrolizumab plus enfortumab vedotin in cisplatin-eligible MIBC.

During an Onclive Peer Exchange, panelists examined the utility of circulating tumor DNA in bladder cancer and other genitourinary malignancies.

Erda-iDRS was safe and produced early efficacy signals in FGFR-altered NMIBC.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, colorectal cancer, breast cancer, chronic myeloid leukemia, and multiple myeloma.

The FDA cleared relacorilant plus nab-paclitaxel in ovarian cancer, the primary end point of the SENTRY trial in myelofibrosis was met, and more.

The NCCN has added the IBCG risk stratification model for intermediate-risk NMIBC to its Clinical Practice Guidelines in Oncology for bladder cancer.

Drs Armstrong and Tawagi spotlight the most practice-informing data to come out of the 2026 Genitourinary Cancers Symposium.

The FDA has cleared nivolumab/AVD for classical Hodgkin lymphoma, accepted a bezuclastinib NDA for review in nonadvanced systemic mastocytosis, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Nadofaragene firadenovec has been added to the NCCN guidelines in BCG-unresponsive papillary NMIBC without CIS.

David B. Solit, MD, discusses ongoing efforts to develop ADCs and other novel treatment approaches beyond EV plus pembrolizumab in urothelial cancer.

The NCCN guidelines in bladder cancer now include nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with papillary-only disease.

The top 5 OncLive TV videos of the week cover insights in colorectal cancer, breast cancer, bladder cancer, and more

A drug withdrawal in follicular lymphoma and epithelioid sarcoma, a CRL in lung cancer, and priority review in breast cancer highlight this week's top oncology news.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA has received a resubmitted sBLA for nogapendekin alfa inbakicept in BCG-unresponsive NMIBC with papillary-only tumors.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, breast cancer, bladder cancer, head and neck cancer, and pancreatic cancer.